BioSpace News Archive

Veracyte, Inc . (Nasdaq: VCYT) today announced new data from two studies that further demonstrate the Decipher ® Prostate Genomic Classifier (GC) provides prognostic information that can help physicians tailor treatment decisions for men with prostate cancer.

jCyte, Inc. , a biotech company dedicated to improving the lives of patients with retinal degenerative diseases, today announced the further expansion of the company’s executive management team with the appointment of John Sholar as General Counsel. Mr. Sholar brings to jCyte more than 20 years of industry experience, serving as the head of North American legal

First clinical trial from BioFactura’s pipeline of high-value biosimilar and biodefense drugs BFI-751: Biosimilar designed to treat people with Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis Study to assess safety and tolerability of 751-BFI and evaluate pharmacokinetics in comparison to Stelara®

Qosina is pleased to announce that it has entered into a distribution agreement with Nordson MEDICAL, a premier manufacturer and supplier of components to the bioprocess and medical device industries.

Xencor, Inc. announced it has entered into a technology license agreement with Bristol-Myers Squibb Company under which Bristol Myers Squibb will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of a novel antibody combination therapy that is intended to neutralize the SARS-CoV-2 virus for treatment or prevention of COVID-19.

Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboration includes initial programs in respiratory disease and ophthalmology, with opportunity to nominate additional programs

Brains Bioceutical has Received Submission Acceptance for a Drug Master File (DMF) from the FDA for its CBD Active Pharmaceutical Ingredient (API) manufactured by its subsidiary BSPG Laboratories in the United Kingdom

Digital health leader, physIQ Inc. , recently announced that Intermountain Healthcare Utah , The University of Texas Health Science Center at Houston (UTHealth) and Rush University Medical Center have joined the NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker. These institutions will serve as recruiting centers and key partners in the Phase II validation stage of this study.

Allscripts and AmerisourceBergen businesses are accelerating the fulfillment of specialty medications through innovation and automation in support of physician practices, patient adherence and better outcomes

Acquisition Strengthens Henry Schein One’s Goal to be the Leading Provider of Dental Analytics Solutions and Services to the Dental Market